• Thomas Karagiannis, Ioannis Avgerinos, Maria Toumpalidou, Aris Liakos, Konstantinos Kitsios, Georgios Dimitriadis, Nikolaos Papanas, Alexandra Bargiota, Iakovos Avramidis, Anastasia Katsoula, Anastasios Tentolouris, Thekla Chatziadamidou, Stathis Giannakopoulos, Stavros Alexiadis, Kalliopi Kotsa, Apostolos Tsapas, and Eleni Bekiari.
• Clinical Research and Evidence-Based Medicine Unit, Second Medical Department, Aristotle University of Thessaloniki, Thessaloniki, Greece. tkaragian@auth.gr.
• J Gen Intern Med. 2020 Jan 2.

BackgroundPatients' views on the relative importance of treatment outcomes and medication attributes for type 2 diabetes may differ from clinicians' perceptions.ObjectiveTo assess which treatment outcomes and medication attributes are considered important by patients and clinicians for therapeutic decisions in type 2 diabetes.DesignExploratory, sequential, mixed-methods design comprising a qualitative (focus groups) and a quantitative (survey) phase.ParticipantsPatients in the focus groups (n = 33) and the survey study (n = 656) were recruited from 4 and 9 diabetes clinics across Greece, respectively. Clinicians in the survey study (n = 363) were identified from Greek registries for healthcare professionals.MeasurementsWe conducted 6 focus groups to obtain patients' views regarding the impact of type 2 diabetes on their lives. Identified themes informed the development of a survey, which aimed to assess which outcomes and medication attributes are considered most important by patients and clinicians. We calculated odds ratios to compare patients' and clinicians' responses.ResultsThe focus groups identified 6 main themes and 15 subthemes. In the survey study, patients were more likely than clinicians to rate prevention of amputation (odds ratio, 9.32; 95% CI, 6.51 to 13.35), diabetic eye disease (6.16; 4.63 to 8.21), sexual dysfunction, and stroke as important, while clinicians were more likely than patients to choose risk for hypoglycemia, and reduction of all-cause mortality, HbA1c, and body weight. Compared with clinicians, patients were less concerned about drug cost (0.16; 0.11 to 0.23), but more concerned about route of administration and need for less frequent glucose self-monitoring.ConclusionsPatients and clinicians differ in the perception of the relative importance of treatment outcomes and drug characteristics. Individual patient preferences should be explored and implemented in the therapeutic decision-making for type 2 diabetes.

5 keywords...

hide…